RESTORE (820292)

  https://cordis.europa.eu/project/id/820292

  Horizon 2020 (2014-2020)

  RESTORE Health by Advanced Therapies (Advanced Therapy Medicinal Products and Biologized Medical Devices) – ALL for Advanced Therapies – with Passion – For Patients

  Preparatory Actions for new FET Flagships (FETFLAG-01-2018)

  pharmaceutical drugs  ·  oncology

  2019-03-01 Start Date (YY-MM-DD)

  2020-07-31 End Date (YY-MM-DD)

  € 1,000,000 Total Cost


  Description

Recently, a new class of “living drugs” has been developed – Advanced Therapies which aim to transform the current focus of “treatment of disease” into one that concentrates on “restoration of health” with promising results in a broad field of Regenerative Medicine, including targeted immune reconstitution for cancer treatment. Advanced Therapies are game changing in Health Care and have a rapidly expanding market size of approximately 12 and 50 bn € expected by 2020 and 2030, respectively. There is great value in European science and technology on Advanced Therapies but Europe has been losing ground because of scattered and underpowered efforts. If Europe wants a leading role in this emerging field in the future, a mission-driven approach is required to make the transforming promise of Advanced Therapies a reality. The development of new Advanced Therapy products and their implementation in clinical practice will enhance the value-based outcome of patients. Measurable by having dozens of premier-league Advanced Therapy Products “discovered & made in Europa” by 2030 and beyond. Bringing affordable, standard-of-care for currently incurable diseases which are accessible for every European citizen who need it to RESTORE Health. We propose a mission-driven programme led by the candidate LSRI RESTORE, aiming to build a coordinated, financially strong European partnership between different areas of interest and cross-sectors involving academia, industry, regulatory authorities, health care, patient organisations, and public society. In order to guarantee a smart start of the LSRI from 2021 onwards, the preparation phase aims to involve the growing RESTORE community even more closely in working groups on identified tasks and to jointly complete the RESTORE agenda for Research & Innovation Actions as well as Coordination & Support Actions. The deliverables of RESTORE will allow Europe to gain a world leading health position within this emerging field.


  Complicit Organisations

1 Israeli organisation participates in RESTORE.

Country Organisation (ID) VAT Number Role Activity Type Total Cost EC Contribution Net EC Contribution
Portugal UNIVERSIDADE DO MINHO (999995505) PT502011378 participant HES € 52,500 € 52,500 € 52,500
Germany MILTENYI BIOTEC BV & CO KG (897602402) DE815828586 participant PRC € 6,250 € 6,250 € 6,250
Italy FONDAZIONE TELETHON ETS (999448716) IT04879781005 participant REC € 52,500 € 52,500 € 52,500
France INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (999997833) FR31180036048 participant REC € 52,500 € 52,500 € 52,500
Germany MILTENYI BIOTEC GMBH (999549305) DE121982110 participant PRC € 8,750 € 8,750 € 8,750
Italy INNOVATION ACTA SRL (910327444) IT13201341008 participant PRC € 587,500 € 587,500 € 587,500
Germany CHARITE - UNIVERSITAETSMEDIZIN BERLIN (999992692) DE228847810 coordinator HES € 105,000 € 105,000 € 105,000
Switzerland UNIVERSITAT ZURICH (999976396) CHE115665634MWST participant HES € 52,500 € 52,500 € 52,500
Germany TISSUSE GMBH (986179504) DE271919708 participant PRC € 15,000 € 15,000 € 15,000
United Kingdom CELL THERAPY CATAPULT LIMITED (949570346) GB154421433 participant REC € 52,500 € 52,500 € 52,500
Israel PLURI BIOTECH LTD (984846336) IL513371666 participant PRC € 15,000 € 15,000 € 15,000